There is substantial evidence of delays in access to innovative medicines in low- and middle- income countries (LMICs). Ongoing monitoring by leading professional organizations such as the European Federation of Pharmaceutical Manufacturers, the Latin American Federation of the Pharmaceutical Industry, and the Pharmaceutical Research and Manufacturers Association of America have documented that delays to access are typically two years or more. Clearly, both demand-side and supply-side factors play a role though their relative importance is unclear. ISPOR has recently launched a new Special Interest Group on Global Access to Medical Innovation including a Working Group on Global Differential Pricing. This workgroup has gathered the available data and literature on access delays and is reviewing the aims, structure, and key features of programs that health technology developers (HTDs) and payers have established to improve access in LMICs. In this workshop, Mikkel Oestergaard, working group co-chair, will present their findings on these delays and the programs that companies, country payers, and regions have developed to address them. Kart Veliste, Silvana Lay, and Marlene Gyldmark are contributors to this literature and are experienced in the issues that payers and companies face in their access negotiations. The The key discussion question will be: given what we know about current access delays and barriers, what steps could be taken toward economists' universally-agreed target of efficient (or "fair") global differential pricing to support the global dynamic efficiency, i.e., the optimal rate of innovation?

This session will stimulate, within the ISPOR community, a discussion of potential policy changes that HTDs and payers could make to better use global differential pricing to improve access to innovative medicines in LMICs.